A 52-week Extension to Study CHTF919N2201 to Evaluate the Safety and Efficacy of Tegaserod (6 mg b.i.d. and 12 mg o.d.) Given Orally for the Treatment of Opioid-induced Constipation (OIC) in Patients With Chronic Non-cancer Pain
Latest Information Update: 09 Aug 2016
At a glance
- Drugs Tegaserod (Primary)
- Indications Constipation
- Focus Registrational; Therapeutic Use
- Sponsors Novartis
- 04 May 2012 New trial record